Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT04474899

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04474899
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04474899. Randomized; quadruple masking; primary purpose treatment. Start 2015-06-24 (actual); primary completion 2024-02-24 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension
Acronym
OHT
Condition
Obesity
Condition
Hypertension
Intervention (Drug)
Moxonidine 0.4 MG
Intervention (Drug)
Amlodipine 5mg
Lead sponsor
Royal Perth Hospital (class: other)
Collaborator
The University of Western Australia (class: other)

Record details

Record id
cardio:ct-nct04474899
Content hash
61d27de21d28a7dda2184df9ed7c3aa30722b3ea7434bde4f6112ba7da7a81d8